Recurrence of uveitis significantly reduces after ATT

Article

Anti-tubercular treatment (ATT) reduces the chances of uveitis recurrence 11-fold

Anti-tubercular treatment (ATT) reduces the chances of uveitis recurrence 11-fold, claims a paper in the British Journal of Ophthalmology.

Professor Soon-Phaik Chee et al., Singapore National Eye Centre, Republic of Singapore, conducted a retrospective review of 182 uveitis patients. Over nine years they were assessed at a single, tertiary institution and completed a minimum of six months follow-up after ATT.

The team measured the clinical characteristics, treatment type, treatment duration and clinical response of each patient. The main outcome measure was the influence of ATT duration on the recurrence of inflammation.

For six months or more 46 patients were administered ATT and 18 patients received ATT for less than six months. Patients who underwent over nine months of ATT were less likely to experience a recurrence in uveitis, compared to patients who did not receive ATT.

Uveitis and latent tuberculosis patients who were administered over nine months of ATT demonstrated an 11-fold decrease in the likelihood of recurrence.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.